Biotechnology

Alligator Publishes Supplement Prospectus

December 3, 2025 12:15 PM

Alligator Bioscience (STO:ATORX) ("Alligator" or the "Company") has prepared a supplement prospectus (the "Supplement Prospectus") to the prospectus regarding invitation to subscribe for units, consisting of ordinary shares and warrants (the "Rights Issue"), which was approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) on 28 November 2025 and published by the Company on the same day (the "Prospectus")....

Read more

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

December 3, 2025 11:00 AM

For a micro-cap biotech, the usual headlines bounce between cash raises, compliance updates, and board-room reshuffles. Once in a while, though, one surfaces that sets the stage for something bigger: science that could rewrite the cancer-treatment script, and a strategy built to survive what's next. That is where LIXTE (NASDAQ:LIXT) stands as of late 2025. Earlier this month, LIXTE cast the spotlight on its lead compound, LB-100, the only...

Read more

Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood

December 3, 2025 8:30 AM

Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, today announced a major strategic advancement in the development of BMND08, transitioning the program into FDA-directed activities using the Company's newly engineered nano-formulation drug-delivery platform,...

Read more

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

December 3, 2025 8:00 AM

Oncology has spent decades chasing the next magic bullet. The twist is that the next breakthrough may not be a bullet at all. It may be an amplifier, the kind of drug that makes every other therapy in the treatment toolbox work harder. LIXTE Biotechnology Holdings (NASDAQ:LIXT) is focused on developing the latter, and its work so far is producing results that may do more than save lives. It may transform the company as well. LB-100 is LIXTE's...

Read more

Alligator Bioscience Publishes Financial Calendar for 2026

December 3, 2025 3:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), hereby publishes its financial calendar for 2026: Deadline for Alligator Bioscience's shareholders to submit resolutions to be considered by the Annual General Meeting 31 January 2026 Year-end report 2025 12 February 2026 Annual report 2025 March 2026 Interim report Q1 2026 5 May 2026 Annual General Meeting 6 May 2026 Interim report H1 2026 27 August 2026 Interim report Q3 2026 22 October...

Read more

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

December 2, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced the publication of "Caring for a Loved One with Alzheimer's Disease: First Hand Experiences," a comprehensive caregiver-focused book sponsored by IGC Pharma and authored by several of the world's leading experts in neuropsychology...

Read more

Faron Pharmaceuticals Ltd: Grant of Options

December 2, 2025 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company's board has confirmed the grant of a total of 180,000 options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019. The Options have been allocated under the Share Option Plan 2019 and are exercisable between 1 December...

Read more

Alligator Bioscience Enters into Additional Subscription Undertakings and Top Guarantee Commitments for the Upcoming Rights Issue

December 1, 2025 1:00 PM

Alligator Bioscience (STO:ATORX) - On 22 October 2025, the Board of Directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company") resolved on an issue of units, consisting of ordinary shares and warrants, with preferential rights for the Company's existing shareholders (the "Rights Issue"), where the final terms were resolved and announced on 24 November 2025. At the time of such announcement, the Rights Issue was covered by...

Read more

Alligator Bioscience Announces Publication of REACtiVe-2 Phase 1 trial data in Nature Communications

December 1, 2025 3:10 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today announced the publication of a peer-reviewed article in Nature communications, reporting data from the REACtiVe-2 clinical trial. REACtiVe-2 is a Phase 1 dose-escalation study evaluating the safety, tolerability and immunological effects of mitazalimab in combination with the dendritic cell-based vaccine MesoPher, developed by Amphera, in patients with metastatic pancreatic ductal...

Read more

Faron Pharmaceuticals Ltd: Appointment of CFO

December 1, 2025 2:15 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company, announces the appointment of Mr. Jurriaan Dekkers as the company's Chief Financial Officer (CFO) as of 1 December 2025. Mr. Dekkers brings more than 20 years of experience in biopharma and healthcare companies. Most recently, he has been the CFO at ProQR Therapeutics, a biotechnology company developing RNA therapies for...

Read more

Increase in Number of Shares and Votes in Vicore Pharma

November 28, 2025 3:30 AM

Vicore Pharma Holding AB (publ) (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs) today announced that the number of shares and votes has increased following the recent directed share issue of approximately USD 48 million (approximately SEK 455 million). The number of outstanding shares and votes increased by 46,915,822 and the share capital increased by 23,457,910.77 SEK. As of...

Read more

Faron's Financial Calendar for 2026

November 27, 2025 2:20 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the following dates for the Company's financial reporting in 2026: 4 March Financial statement release for the full year 2025 and Annual Report 2025 including financial statements for the full year 26 August Half-year financial report for the period January 1 to June 30, 2026 The...

Read more

FluoGuide A/S Publishes Interim Report Q3 2025

November 27, 2025 1:40 AM

FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO) today releases its results for the period 1 January - 30 September 2025. The Q3 report is available as an attached document to this press release and on FluoGuide's website. Operational Highlights - Q3 2025 Entered a collaboration with Olympus, a world leading MedTech company in endoscopic imaging Received positive FDA feedback on FG001 in high-grade glioma Highlights after the end of Q3...

Read more

Lir Life Sciences Announces Engagement for IR Services

November 26, 2025 5:00 PM

Lir Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has engaged MCS Market Communication Service GmbH (business address: Saarlandstraße 28 58511 Lüdenscheid, Germany, email: [email protected]; telephone: +491772481220; and website: www.mcsmarket.de) ("MCS") for the provision of a range of online marketing services, including campaign creation, production of marketing materials, as well as...

Read more

IVF CRYO Urges Greater Awareness Around Safe Embryo and Egg Transport

November 26, 2025 11:30 AM

IVF CRYO, LLC, a leading reproductive tissue transport company based in Fishers, Indiana, is raising awareness about the critical need for safe, standardised shipping of human embryos, eggs, and sperm across the United States and internationally. As more families turn to fertility treatments, IVF CRYO is calling attention to a growing gap in patient understanding and industry regulation around how reproductive tissue is moved between clinics....

Read more

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

November 26, 2025 8:48 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Live Virtual Investor CEO Connect segment on Wednesday, December 3, 2025 at 4:00 PM ET. As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's recent news and next steps. In addition to the moderated discussion, there will be a...

Read more

Good Salt Life, Inc.'s Induction Charge Delivery Systems Deployed to Protect Show Horses from Widespread EHV-1 Outbreak

November 26, 2025 8:00 AM

In response to the devastating outbreak of Equine Herpesvirus-1 (EHV-1) linked to the WPRA event in Waco, Texas, Good Salt Life, Inc., a wholly owned subsidiary of NDT Pharmaceuticals (OTC:NDTP), is urgently deploying its safe, EPA-registered disinfectants and innovative chemical delivery systems to combat this critical situation affecting the equine community. Tragically, many performance horses have succumbed to this recent outbreak, and a...

Read more

Two New Studies with DiviTum TKa Presented at SABCS 2025

November 26, 2025 3:00 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces the presentation of two new abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS). Both studies highlight the clinical relevance of DiviTum® TKa as a dynamic biomarker for monitoring treatment response and pave the way for increased clinical uptake of the test. "These studies further demonstrate the value...

Read more

Biomind Labs Announces Revocation of Cease Trade Order

November 25, 2025 5:20 PM

Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that the Ontario Securities Commission (the "Commission") has revoked its cease trade order issued on April 4, 2025 (the "FFCTO") against the Company effective November 25, 2025. The Company was cease traded by the Commission for failure to file audited financial statements for the year ended December 31, 2024, corresponding management's discussion and analysis and...

Read more

FluoGuide Signs Collaboration Agreement with ZEISS

November 25, 2025 9:15 AM

FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 25 November 2025 - FluoGuide A/S, a biotech company specializing in precision cancer surgery, announces a signed collaboration agreement with ZEISS Medical Technologies. The objective of the collaboration is to develop FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The focus of the current agreement is to support the clinical phase. The agreement has no initial...

Read more